146 related articles for article (PubMed ID: 29096333)
21. Adiponectin signals through Adiponectin Receptor 1 to reverse imatinib resistance in K562 human chronic myeloid leukemia cells.
Wu S; Zheng C; Chen S; Lin B; Chen Y; Zhou W; Li Z
Biochem Biophys Res Commun; 2015 Jan; 456(1):367-72. PubMed ID: 25475722
[TBL] [Abstract][Full Text] [Related]
22. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].
Wang XD; Qiu L; Lu RZ; Chen LJ; Zhan ZM; Han BH; Zhang BL; Ma J
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3399-405. PubMed ID: 18476538
[TBL] [Abstract][Full Text] [Related]
23. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
24. Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
Bandyopadhyay S; Li J; Traer E; Tyner JW; Zhou A; Oh ST; Cheng JX
PLoS One; 2017; 12(7):e0179558. PubMed ID: 28719608
[TBL] [Abstract][Full Text] [Related]
25. Knock-down of CIAPIN1 sensitizes K562 chronic myeloid leukemia cells to Imatinib by regulation of cell cycle and apoptosis-associated members via NF-κB and ERK5 signaling pathway.
Wang J; Li Q; Wang C; Xiong Q; Lin Y; Sun Q; Jin H; Yang F; Ren X; Pang T
Biochem Pharmacol; 2016 Jan; 99():132-45. PubMed ID: 26679828
[TBL] [Abstract][Full Text] [Related]
26. Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.
Kim DS; Na YJ; Kang MH; Yoon SY; Choi CW
Korean J Intern Med; 2016 Mar; 31(2):357-66. PubMed ID: 26874514
[TBL] [Abstract][Full Text] [Related]
27. Effect of Dasatinib on Genes Related to Mitotic Catastrophe Pathway in Chronic Myeloid Leukemia Cells.
Kipcak S; Ozel B; Avci CB; Takanlou LS; Takanlou MS; Gunduz C; Gunel NS
Anticancer Agents Med Chem; 2021; 21(13):1724-1731. PubMed ID: 33155931
[TBL] [Abstract][Full Text] [Related]
28. RalA, a GTPase targeted by miR-181a, promotes transformation and progression by activating the Ras-related signaling pathway in chronic myelogenous leukemia.
Gu C; Feng M; Yin Z; Luo X; Yang J; Li Y; Li T; Wang R; Fei J
Oncotarget; 2016 Apr; 7(15):20561-73. PubMed ID: 26967392
[TBL] [Abstract][Full Text] [Related]
29. CUEDC2 sensitizes chronic myeloid leukemic cells to imatinib treatment.
Zhang H; Chang G; Wang J; Lin Y; Ma L; Pang T
Leuk Res; 2013 Nov; 37(11):1583-91. PubMed ID: 24125838
[TBL] [Abstract][Full Text] [Related]
30. Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines.
Wang Q; Ding W; Ding Y; Ma J; Qian Z; Shao J; Li Y
Oncotarget; 2017 Jun; 8(23):37594-37604. PubMed ID: 28410239
[TBL] [Abstract][Full Text] [Related]
31. Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway.
Liu Z; Li Y; Lv C; Wang L; Song H
Biochem Biophys Res Commun; 2016 Sep; 478(2):893-9. PubMed ID: 27520370
[TBL] [Abstract][Full Text] [Related]
32. BM microenvironmental protection of CML cells from imatinib through Stat5/NF-κB signaling and reversal by Wogonin.
Xu X; Zhang X; Liu Y; Yang L; Huang S; Lu L; Wang S; Guo Q; Zhao L
Oncotarget; 2016 Apr; 7(17):24436-54. PubMed ID: 27027438
[TBL] [Abstract][Full Text] [Related]
33. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Rahmani M; Nguyen TK; Dent P; Grant S
Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
[TBL] [Abstract][Full Text] [Related]
34. Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation.
Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Wang X; Shi X; Liu J
Cell Death Dis; 2017 Jul; 8(7):e2913. PubMed ID: 28682311
[TBL] [Abstract][Full Text] [Related]
35. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
36. Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.
Wang W; Zhang J; Li Y; Yang X; He Y; Li T; Ren F; Zhang J; Lin R
Cancer Lett; 2015 Jan; 356(2 Pt B):791-9. PubMed ID: 25449787
[TBL] [Abstract][Full Text] [Related]
37. Ginkgetin inhibits proliferation of human leukemia cells via the TNF-α signaling pathway.
Pan LL; Wu WJ; Zheng GF; Han XY; He JS; Cai Z
Z Naturforsch C J Biosci; 2017 Oct; 72(11-12):441-447. PubMed ID: 28902633
[TBL] [Abstract][Full Text] [Related]
38. Potent antitumor activities of recombinant human PDCD5 protein in combination with chemotherapy drugs in K562 cells.
Shi L; Song Q; Zhang Y; Lou Y; Wang Y; Tian L; Zheng Y; Ma D; Ke X; Wang Y
Biochem Biophys Res Commun; 2010 May; 396(2):224-30. PubMed ID: 20398626
[TBL] [Abstract][Full Text] [Related]
39. MiR-124-3p/B4GALT1 axis plays an important role in SOCS3-regulated growth and chemo-sensitivity of CML.
Liu YX; Wang L; Liu WJ; Zhang HT; Xue JH; Zhang ZW; Gao CJ
J Hematol Oncol; 2016 Aug; 9(1):69. PubMed ID: 27516205
[TBL] [Abstract][Full Text] [Related]
40. Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML).
Liu F; Wang B; Wang Q; Qi Z; Chen C; Kong LL; Chen JY; Liu X; Wang A; Hu C; Wang W; Wang H; Wu F; Ruan Y; Qi S; Liu J; Zou F; Hu Z; Wang W; Wang L; Zhang S; Yun CH; Zhai Z; Liu J; Liu Q
Oncotarget; 2016 Jul; 7(29):45562-45574. PubMed ID: 27322145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]